Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article from MarketBeat Media
3 Dividend Aristocrats Whose Yields Can Help Combat InflationAuthor: Chris Markoch. Posted: 4/9/2026. 
Key Points
- Dividend Aristocrats including Amcor, Chevron, and AbbVie can provide reliable income streams that can help offset persistent inflation.
- Each of those three companies offers a yield above 3% combined with decades of consistent dividend growth, signaling strong financial stability.
- These stocks also provide exposure to defensive sectors like packaging, energy, and health care, which tend to perform well during periods of elevated inflation.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
The calendar says it’s spring, but investors can’t be blamed for feeling like it’s Groundhog Day: the economic issues weighing on portfolios continue to persist. Just after a ceasefire between the United States and Iran was announced, which provided a market tailwind, investors are now digesting the latest inflation readings that look to be making an unwanted comeback. The Personal Consumption Expenditures (PCE) index and the Consumer Price Index (CPI) for March are both due this week, and each report is expected to show inflation creeping higher. Analysis suggests stickier inflation remains a risk.
Elon Musk believes this technology could make Tesla the most valuable company in the world — yet the core infrastructure powering it is not owned by Tesla at all.
It belongs to one of Musk's private ventures, with thousands of systems already running globally around the clock. Veteran tech investor Matt McCall has identified a little-known way everyday investors can gain exposure.
The stock is currently trading for less than $30. Reveal the ticker now
Concerningly, the inflation data so far doesn’t yet reflect the full impact of higher oil prices, which are typically inflationary. Whether that effect proves to be a short-term headwind or a longer-term problem remains to be seen. There are multiple layers to the inflation picture. Even if oil prices fall and the economy strengthens, stronger demand can be inflationary. Interest rates matter as well: the Federal Reserve has paused rate cuts, and some market participants expect the next move in rates could be upward. Given that inflation is unlikely to reach the Fed’s 2% target anytime soon, one strategic move for investors is to consider dividend stocks yielding more than 3%. Even if stock prices are range-bound, dividend growth can help returns outpace inflation. Rather than simply chasing yield, a better approach is to target companies with a long history of paying and reliably growing dividends. That describes the following three Dividend Aristocrats, each of which has raised its payout for at least 25 consecutive years. Amcor Offers High Yield With Defensive DemandAmcor (NYSE: AMCR) is a global packaging company with market leadership in food and beverage, pharmaceutical, and personal care packaging. Its products tend to remain in demand, particularly when companies seek ways to reduce input costs. AMCR has been roughly flat over the past 12 months, but its dividend looks secure. The company has increased its payout for 27 consecutive years, a streak that includes dividends inherited from its 2019 Bemis acquisition. As of April 9, the yield is 6.3%, and the annual payout per share is $2.60. Amcor faces cost pressures from tariffs and higher oil prices. At roughly 27x earnings, AMCR trades at a premium to its historical average and the broader market. Still, the dividend appears secure, and analysts have a consensus one-year price target of $52 on AMCR, which would imply a gain of more than 20% in addition to its sizable yield. Chevron Combines Energy Exposure With Dividend StrengthEnergy stocks have been volatile since the conflict with Iran began in late February. Chevron (NYSE: CVX) has been one of the beneficiaries. Year to date, CVX is up almost 30%. If oil prices remain elevated, investors will be glad they held CVX. Even if oil prices retreat, Chevron remains a best-in-class oil stock that is expanding output not only in the United States but also more recently in Venezuela. As an integrated major, Chevron has meaningful exposure to liquefied natural gas and strategic investments in renewable energy. The recent rally has pushed CVX’s valuation higher, but investors should focus on the long-term track record. In 2025, the company generated $20.2 billion in free cash flow and returned a record $27 billion to shareholders through dividends and buybacks. Chevron’s dividend yields 3.6%, equivalent to $7.12 per share annually. Chevron has increased its dividend for 38 consecutive years. AbbVie Delivers Reliable Growth and Income in Health CareHealth care isn’t the first sector investors think of for inflation protection. But people don’t stop filling prescriptions when prices rise, and that durability makes AbbVie (NYSE: ABBV) worth a closer look. For the full year 2025, AbbVie reported record revenue of $61.2 billion, with immunology revenue up 14%, led by flagship treatments Skyrizi and Rinvoq. Those drugs have helped fill the revenue gap left by Humira’s patent expiration. While that shift was a concern for some analysts, ABBV has continued to increase its payout and now boasts a dividend streak of 52 consecutive years. The yield is 3.3%, equal to $6.92 per share annually. AbbVie is more a stock to own for long-term income and compounding than to trade actively. |
0 Response to "We're excited to have you on board"
Post a Comment